E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Published on 7/16/2007 in the Prospect News Special Situations Daily.

Blackstone Group affiliate to finance ReAble's $1.5 billion acquisition of DJO

By Lisa Kerner

Charlotte, N.C., July 16 - DJO Inc. agreed to be acquired by an affiliate of ReAble Therapeutics, Inc. in a deal valued at $1.6 billion including debt.

A definitive agreement between the two companies calls for DJO shareholders to receive $50.25 per share in cash. The offer price is a 25% premium over DJO's average closing share price for the 30 trading days ended July 13.

DJO has a 50-day go-shop period for superior proposals. An $18.7 million break-up fee is included in the agreement.

An affiliate of the Blackstone Group is the controlling shareholder of ReAble and has committed to provide the equity financing needed to complete the transaction, a company news release stated.

DJO's board, along with its transaction committee, unanimously approved the agreement and recommends that DJO stockholders approve the merger. The transaction is expected to close in the fourth quarter of 2007.

The companies both offer complementary products in orthopedic rehabilitation and pain management for an "absolutely compelling" strategic fit, according to ReAble chief executive officer Ken Davidson in a news release.

DJO was advised by Wachovia Securities and Latham & Watkins LLP. ReAble was advised by Credit Suisse and Simpson Thatcher & Bartlett LLP.

Vista, Calif.-based DJO specializes in rehabilitation and regeneration products for the non-operative orthopedic, spine and vascular markets.

ReAble, located in St. Louis, manufactures and distributes orthopedic devices to musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events and sports-related injuries.

Acquirer:ReAble Therapeutics, Inc.
Target:DJO Inc.
Transaction total:$1.6 billion
Price per share:$50.25
Break-up fee:$18.7 million
Announcement date:July 16
Expected closing:Fourth quarter of 2007
Stock price for target:NYSE: DJO; $42.10 on July 13

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.